| Aivaliotis, Lee et al. 2017 [44] | USA | Quasi 2 group | Async | Chronic pancreatitis | 1 | Efficacy, Quality |
|
|
| 52.9 | 4.00 | Positive |
| Albert, Dinesen et al. 2017 [45] | Multicenter USA | Descriptive, Cross-sectional | Mixed | CHF | 1 | Quality | 16.50 |
|
| 63.5 | 0.06 | Positive |
| Cobos-Campos, Fernández de Larrinoa et al. 2017 [46] | Spain | RCT | Async | Smoking | 1 | Efficacy |
|
|
| 44.9 | 24.00 | Positive |
| Dario, Saccavini et al. 2017 [47] | Italy | Quasi 1 group pre post | RPM | Diabetes | 1 | Efficacy |
| 43.00 |
| 73.05 | 52.00 | Negative |
| Guilkey, Draucker et al. 2018 [48] | USA | OBS 1 group | Mixed | Pain | 1 | Quality | 28.00 | 12.00 |
| 55 | 52.00 | Positive |
| Kotsani, Antonopoulou et al. 2018 [49] | Greece | RCT | Sync | Diabetes | 1 | Efficacy |
| 47.90 |
|
| 12.00 | Positive |
| Kurland, Anna et al. 2018 [50] | USA | Quasi 1 group pre post | Mixed | Stroke | 1 | Efficacy |
| 38.00 |
| 66.4 | 24.00 | Positive |
| Kamei, Yamamoto et al. 2018 [49] | Japan | Quasi 1 group pre post | Mixed | MCC | 3 | Adherence, Efficacy, Quality |
| 55.60 | Urban | 76.1 | 12.00 | Positive |
| Oddone, Gierisch et al. 2018 [51] | USA Multicenter | RCT | Sync | MCC | 3 | Efficacy, Utilization |
| 15.00 |
| 56 | 24.00 | Positive |
| Taylor, Oddone et al. 2018 [52] | USA | Quasi 1 group pre post | Sync | Arthritis | 1 | Efficacy | 50.00 | 9.30 |
| 61.1 | 52.00 | Positive |
| Hamar, Coberley et al. 2018 [53] | Australia | Retrospective Matched | Sync | MCC | 7 | Utilization |
| 50.90 |
|
| 0.00 | Positive |
| Harnett, Jones et al. 2018 [54] | UK | Quasi 2 group | RPM | Chronic Kidney Disease | 1 | Efficacy, Utilization |
| 45.00 |
| 78.5 | 52.00 | Positive |
| Cameron, Voth et al. 2018 [55] | Canada | Retrospective | Sync | MCC | 1 | Efficacy |
| 70.20 |
|
| 6.00 | Positive |
| Litke, J., et al. 2018 [56] | USA | Quasi 2 group | Sync | MCC | 4 | Efficacy |
|
|
| 62 | 19.00 | Positive |
| Bakas, Sampsel et al. 2018 [57] | USA | Quasi 2 group | Sync | MCC | 7 | Efficacy | 0.00 | 71.00 | Urban | 82.7 | 19.20 | Positive |
| Herold, van den Berg et al. 2018 [58] | Germany | Retrospective Matched | RPM | CHF | 5 | Efficacy |
| 45.86 | Mixed | 74.44 | 104.00 | Positive |
| Herold, Hoffmann et al. 2018 [59] | Germany | Retrospective | Mixed | CHF | 1 | Cost |
| 45.00 | Mixed | 73.7 | 104.00 | Positive |
| Walker, Pompilio et al. 2018 [60] | UK | RCT | RPM | MCC | 1 | Efficacy, Cost, Utilization |
| 71.00 |
|
| 36.00 | Positive |
| Frederix, Vanderlinden et al. 2019 [61] | Belgium | RCT | RPM | CHF | 1 | Efficacy, Cost, Utilization |
| 51.00 |
| 76 | 24.00 | Positive |
| Brain, Reynolds et al. 2019 [63] | USA | Quasi 1 group pre post | Sync | Diabetes | 1 | Efficacy, Quality, Utilization | 26.00 | 64.00 | Urban |
| 65.00 | Positive |
| Piette, Striplin et al. 2020 [63] | USA | RCT | Async | MCC | 5 | Utilization | 53.70 | 60.70 |
| 80.2 | 4.00 | Positive |